BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Proteolysis Targeting Chimeras (PROTACs) technology as potential new method for mosquito-borne disease control
ELREXFIO’s label contains a boxed warning for cytokine release syndrome and neurologic toxicity
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
The company has secured 506 marketing approvals for its oncology products across 76 countries.
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
Subscribe To Our Newsletter & Stay Updated